255 related articles for article (PubMed ID: 33421978)
1. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY
Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978
[TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
3. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
4. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.
Scoville SD; Cloyd JM; Pawlik TM
Expert Opin Pharmacother; 2020 Feb; 21(2):183-191. PubMed ID: 31760823
[No Abstract] [Full Text] [Related]
5. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
Cloyd JM; Konda B; Shah MH; Pawlik TM
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
7. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.
Keutgen XM; Schadde E; Pommier RF; Halfdanarson TR; Howe JR; Kebebew E
Semin Oncol; 2018 Aug; 45(4):232-235. PubMed ID: 30318110
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
Perez K; Chan J
Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
10. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
[TBL] [Abstract][Full Text] [Related]
11. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
Rev Endocr Metab Disord; 2018 Jun; 19(2):145-158. PubMed ID: 29464446
[TBL] [Abstract][Full Text] [Related]
12. Local treatment for focal progression in metastatic neuroendocrine tumors.
Al-Toubah T; Partelli S; Cives M; Andreasi V; Silvestris F; Falconi M; Anaya DA; Strosberg J
Endocr Relat Cancer; 2019 Apr; 26(4):405-409. PubMed ID: 30668527
[TBL] [Abstract][Full Text] [Related]
13. [Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].
Holzer K
Chirurg; 2014 Aug; 85(8):731-44. PubMed ID: 25103842
[TBL] [Abstract][Full Text] [Related]
14. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
15. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
Cives M; Soares HP; Strosberg J
Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
[TBL] [Abstract][Full Text] [Related]
16. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
17. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Cives M; Strosberg J
Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
[TBL] [Abstract][Full Text] [Related]
18. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
[TBL] [Abstract][Full Text] [Related]
19. An update on gastroenteropancreatic neuroendocrine tumors.
Cives M; Strosberg J
Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471
[TBL] [Abstract][Full Text] [Related]
20. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
Thomas KEH; Voros BA; Boudreaux JP; Thiagarajan R; Woltering EA; Ramirez RA
Oncologist; 2019 Aug; 24(8):1076-1088. PubMed ID: 30635447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
